Dr Min-Han Tan is the Founder, CEO and Medical Director of Lucence. The Company develops advanced liquid biopsy blood tests that profile the hallmarks of cancer to the deepest limit to achieve timely tailored treatment and earlier detection. Headquartered in Palo Alto and Singapore, with offices in Hong Kong and Suzhou, its clinical services are delivered worldwide through twin CLIA-licensed laboratories in the United States and Singapore.

Dr Tan received his medical degree and PhD from the National University of Singapore, graduating with gold medals. He completed two specialist medical oncology and clinical cancer genetics fellowships at the National Cancer Centre Singapore and the Cleveland Clinic, USA, respectively. He joined the Agency for Science, Technology and Research (A*STAR), Singapore in 2011 to lead the Laboratory of Systems Medicine. Dr Tan subsequently founded Lucence in 2016 to commercialize the liquid biopsy technologies that his lab developed at A*STAR.

Dr Tan has published over 100 original research publications with a special focus on innovative cancer diagnostics, and filed more than 12 patents. His research laboratory is recognized for the landmark discovery of circulating tumor-endothelial cell clusters in the blood of cancer patients, which overturned a 50-year scientific dogma. Dr Tan's track record of disruptive innovation has been recognized with awards from the American Society of Clinical Oncology, the European Society of Medical Oncology and the Association of Southeast Asian Nations. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.